HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
MWN-AI** Summary
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company based in the U.S., is set to present three posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 5-9, 2025, in National Harbor, Maryland. The company focuses on developing innovative immunotherapies aimed at extending healthspan and addressing diseases linked to chronic inflammation.
The posters will highlight results from IND-enabling studies for HCW Biologics' leading drug candidates, which utilize their proprietary T-Cell Receptor ?-Chain Constant Region (TRBC) platform technology. This platform allows for the creation of various classes of immunotherapeutic compounds, including multi-functional immune cell stimulators, second-generation immune checkpoint inhibitors, and multi-specific targeting fusions.
On November 7, the first poster will showcase a novel bispecific T-cell engager molecule designed for cancer therapy. The second poster will follow on November 8, presenting a tetra-specific immunotherapeutic based on pembrolizumab, a well-known checkpoint inhibitor. The final poster, also presented on November 8, will discuss a novel cytokine fusion molecule that enhances immune cell responses and support for CAR-T therapies and lymphocytes.
HCW Biologics aims to revolutionize the treatment landscape for various diseases associated with chronic inflammation, including types of cancer and autoimmune conditions. With over 50 molecules developed using the TRBC platform, the company is committed to advancing its promising candidates through preclinical evaluations. These advancements underscore HCW Biologics' potential impact on improving patient quality of life and extending longevity through targeted and effective immunotherapy.
MWN-AI** Analysis
HCW Biologics Inc. (NASDAQ: HCWB) is positioning itself at the forefront of immunotherapy innovation, especially with its upcoming presentations at the Society for Immunotherapy of Cancer annual meeting. Analysts should closely monitor this event as it represents a critical opportunity for the company to showcase its proprietary T-Cell Receptor Beta Constant (TRBC) platform.
The presentation of three posters—highlighting class-specific immunotherapeutics—could catalyze investor interest and potentially affect HCWB's stock performance. The innovative approaches, from multi-specific targeting fusions to second-generation immune checkpoint inhibitors, may suggest a robust pipeline and enhanced therapeutic potential against various cancers and inflammatory conditions.
Given the industry's increasing focus on therapies that address chronic inflammation-related diseases, HCWB’s research may resonate well with current market trends favoring such innovations. It's crucial to assess the contents of the posters and any feedback from key opinion leaders during the conference, as positive discussions could bolster investor confidence.
Investors should also consider the timing of these presentations in relation to the overall market sentiment. If HCWB secures favorable attention and solid data to back their claims, it may serve as a strong catalyst for upward stock movement post-event. On the other hand, if results do not meet expectations or if competitive landscapes in immunotherapy rapidly shift, there could be downside risks to evaluate.
Overall, while HCWB is leading with innovative studies that have the potential to establish significant market footholds, the inherent risks associated with clinical-stage biotech firms necessitate due diligence. Investors should maintain a balanced view, weighing the uncertain outcomes against the promising potential of HCWB's immunotherapies as the company navigates this critical phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, will present three posters to showcase the results of the IND enabling studies of the Company’s lead drug candidates based on its novel proprietary TRBC platform technology, at the upcoming 40 th Annual Meeting of the Society for Immunotherapy of Cancer, taking place from November 5 to 9, 2025 in National Harbor, Maryland.
The Company’s T-Cell Receptor ?-Chain Constant Region platform (“TRBC platform”) is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers.
The Company’s poster presentations will take place on November 7 and November 8:
Poster 1: A Multi-Specific Targeting Fusion and Enhanced Immune Cell Engager (Class III TRBC Compound)
Title : A novel multi-functional bispecific T-cell engager molecule for cancer therapy
Abstract Number : 915
Session Date and Time : November 7, 2025, 12:15-1:45 pm, 5:35–7:00 pm ET
Location : Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
Poster 2: Second-Generation Immune Checkpoint Inhibitors (Class II TRBC Compound)
Title : A novel tetra-specific pembrolizumab-based immunotherapeutic
Abstract Number : 1014
Session Date and Time : November 8, 2025, 12:15-1:45 pm, 5:10-6:35 pm ET
Location : Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
Poster 3: Multi-Functional Immune Cell Stimulators (Class I TRBC Compound)
Title : Enhancing immune cell expansion, checkpoint inhibitor synergy, and i n vivo CAR-T and lymphocyte support using HCW11-006 -- a novel cytokine fusion molecule
Abstract Number : 276
Session Date and Time : November 8, 2025, 12:15-1:45 pm, 5:10- 6:35 pm ET
Location : Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include the actual success and potency of the Company’s TRBC platform molecules. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.
Company Contact:
Dr. Peter Rhode
Chief Scientific Officer and Vice President of Clinical Operations
HCW Biologics Inc.
PeterRhode@HCWBiologics.com
FAQ**
How does HCW Biologics Inc. HCWB plan to differentiate its TRBC platform from existing immunotherapy technologies in terms of clinical efficacy and patient outcomes?
What specific conditions or diseases does HCW Biologics Inc. HCWB prioritize in its pipeline for immunotherapeutic development, and how does this align with current unmet medical needs?
Can you provide insights into the preclinical evaluation studies being conducted for HCW Biologics Inc. HCWB's TRBC platform molecules, and what key metrics are being used to assess their promise?
What risks and uncertainties does HCW Biologics Inc. HCWB identify in its forward-looking statements regarding the success of its TRBC platform in clinical settings, as mentioned in your recent press release?
**MWN-AI FAQ is based on asking OpenAI questions about HCW Biologics Inc. (NASDAQ: HCWB).
NASDAQ: HCWB
HCWB Trading
194.2% G/L:
$1.015 Last:
297,600,655 Volume:
$1.11 Open:
